

Eric S Daar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8081630/publications.pdf>

Version: 2024-02-01

27
papers

1,383
citations

758635

12
h-index

610482

24
g-index

81
all docs

81
docs citations

81
times ranked

1756
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. <i>Journal of Infectious Diseases</i> , 2011, 203, 1791-1801.	1.9	435
2	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. <i>New England Journal of Medicine</i> , 2021, 385, 595-608.	13.9	359
3	Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. <i>Annals of Internal Medicine</i> , 2011, 154, 445.	2.0	287
4	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. <i>Clinical Infectious Diseases</i> , 2019, 68, 1877-1886.	2.9	42
5	Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia. <i>Journal of Virology</i> , 2014, 88, 10200-10213.	1.5	33
6	Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2018, 218, 1551-1559.	1.9	28
7	Progressive brain atrophy in chronically infected and treated HIV+ individuals. <i>Journal of NeuroVirology</i> , 2019, 25, 342-353.	1.0	26
8	Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3731-3740.	2.0	22
9	Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California. <i>Annals of Epidemiology</i> , 2015, 25, 1-6.	0.9	20
10	Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S63-S69.	1.9	17
11	Real-time and Wireless Assessment of Adherence to Antiretroviral Therapy With Co-encapsulated Ingestion Sensor in HIV-Infected Patients: A Pilot Study. <i>Clinical and Translational Science</i> , 2020, 13, 189-194.	1.5	16
12	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1151-1158.	2.0	16
13	Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access. <i>Fertility and Sterility</i> , 2006, 85, 298-300.	0.5	14
14	Emtricitabine + tenofovir alafenamide for the treatment of HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 427-432.	0.9	10
15	Antiretroviral Therapy. <i>Infectious Disease Clinics of North America</i> , 2014, 28, 439-456.	1.9	9
16	Novel approaches to HIV therapy. <i>F1000Research</i> , 2017, 6, 759.	0.8	9
17	Improving adherence to antiretroviral therapy. <i>Aids Reader</i> , 2003, 13, 81-2, 85-6, 88-90.	0.3	9
18	Condomless Sex With Virologically Suppressed HIV-Infected Individuals. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 149.	3.8	7

#	ARTICLE	IF	CITATIONS
19	Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 358-366.	0.9	7
20	Reply to Antonucci et al.. <i>Journal of Infectious Diseases</i> , 2005, 192, 704-705.	1.9	4
21	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 179-187.	0.7	4
22	HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. <i>HIV Clinical Trials</i> , 2017, 18, 67-74.	2.0	3
23	Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results. <i>Open Forum Infectious Diseases</i> , 2017, 4, S735-S735.	0.4	3
24	CD8+Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection. <i>Viral Immunology</i> , 2018, 31, 525-536.	0.6	2
25	280. Burden of Hyperglycemia in Patients Receiving Dexamethasone for Severe COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, S245-S246.	0.4	0
26	Antiretroviral resistance in clinical practice. <i>Journal of the International Association of Providers of AIDS Care</i> , 2003, 2 Suppl 1, S4-18.	1.2	0
27	New approaches and resolve may define the future of the global HIV pandemic. <i>Research Initiative, Treatment Action: RITA</i> , 2007, 12, 8-10.	0.1	0